Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Mar 18;10(4):957–965. doi: 10.1111/1759-7714.13035

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

(a) The proportions of different sampling procedures in patients who underwent re‐biopsy, () CT‐guided PCNB, () Effusion drainage, () TBNA/EBUS‐TBNA, () SLNB and () other metastasis biopsy. The distribution of results in patients who were tested for EGFR mutation via (b) tissue (c) or plasma. () Consistent with baseline, () Mut plus T790M/T790M, () Wild type, and () others. “Others” in (b) include three patients with small‐cell lung cancer, two with baseline mutations and c‐MET, one with an exon 20 insert, one with translation from 19del to L858R, one with KRAS and one with ALK. “Others” in (c) include one patient with an exon 20 insert and one with baseline mutations (L858R), S768I, and T790M. CT, computed tomography; EBUS, endobronchial ultrasonography; mut plus T790M, patients harbored a baseline mutation and a T790M mutation when re‐tested; PCNB, percutaneous core needle biopsy; SLNB, superficial lymph node biopsy; TBNA, transbronchial needle aspiration; T790M, patients only harbored a T790M mutation and the baseline sensitive mutation disappeared.

Inline graphic — (a) The proportions of different sampling procedures in patients who underwent re‐biopsy, () CT‐guided PCNB, () Effusion drainage, () TBNA/EBUS‐TBNA, () SLNB and () other metastasis biopsy. The distribution of results in patients who were tested for EGFR mutation via (b) tissue (c) or plasma. () Consistent with baseline, () Mut plus T790M/T790M, () Wild type, and () others. “Others” in (b) include three patients with small‐cell lung cancer, two with baseline mutations and c‐MET, one with an exon 20 insert, one with translation from 19del to L858R, one with KRAS and one with ALK. “Others” in (c) include one patient with an exon 20 insert and one with baseline mutations (L858R), S768I, and T790M. CT, computed tomography; EBUS, endobronchial ultrasonography; mut plus T790M, patients harbored a baseline mutation and a T790M mutation when re‐tested; PCNB, percutaneous core needle biopsy; SLNB, superficial lymph node biopsy; TBNA, transbronchial needle aspiration; T790M, patients only harbored a T790M mutation and the baseline sensitive mutation disappeared.